Skip to main content

Advertisement

SpringerLink
Log in

Advances in Management of Psychosis in Neurodegenerative Diseases

  • Dementia (J Pillai, Section Editor)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Abstract

Purpose of the review

Psychosis is broadly defined as a disengagement from reality. It describes syndromes that impair both thought content and thought process. Psychosis negatively impacts an individual’s quality of life, in addition to the families caring for them. Psychosis with different types of hallucinations and delusions occurs in the context of delirium. Neuropsychiatric symptoms (NPS) are almost universal in the course of common neurodegenerative disorders (NDD) like Alzheimer’s disease (AD) or Parkinson’s disease (PD).

In this paper, the authors took an effort to characterize AD and PD psychosis with a special focus on the most diagnostically reliable features. Effectiveness and limitations of pharmacological interventions are discussed.

Recent findings

Consensus diagnostic criteria have evolved for psychosis secondary to AD as well as psychosis in PD. Psychotropic medications can be effective in the treatment of NPS in NDD; however, clinicians must be mindful of the side effects. There is a consensus on benefit of initiating any acetylcholinesterase inhibitor (ACHI: donepezil, rivastigmine, and galantamine) as a first line of treatment for psychosis in AD, as it may reduce and/or avoid the need for the use antipsychotics. Pimavanserin, a selective-serotonin inverse agonist that preferentially targets 5-HT2A receptors, while avoiding activity at dopamine and other receptors commonly targeted by antipsychotics had recently been approved by FDA to treat hallucinations and delusions in PD. Quetiapine is widely prescribed for the treatment of psychosis in different NDD, but the data remains equivocal.

Summary

Psychosis with different types of hallucinations and delusions may occur in the context of delirium and is almost universal as a neuropsychiatric symptom in the course of PD and AD. Currently, pimavanserin remains the only pharmacologic agent approved for treatment of psychosis in PD. In cases of other NPS in other than Parkinson’s diseases, atypical antipsychotics are commonly used off-label. More research is greatly needed to advance this field and address NPS especially psychosis in geriatric population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: APA; 2013.

    Book  Google Scholar 

  2. Gautam S, Jain A, Gautam M, Gautam A. Clinical practice guideline for management of psychoses in elderly. Indian J Psychiatry. 2018;60(3):363–70.

    Google Scholar 

  3. Javadpou A, Sehatpour M, Mani A, Sahraian A. Assessing diagnosis and symptoms profile of late life psychosis among an elderly population. Am J Geriatr Psychiatr. 2013;21(3):159–60.

    Article  Google Scholar 

  4. Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer’s disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatr. 2005;162(11):2022–30.

    Article  Google Scholar 

  5. Zuidema S, Koopmans R, Verhey F. Prevalence and predictors of neuropsychiatric symptoms in cognitively impaired nursing home patients. J Geriatr Psychiatry Neurol. 2007 Mar;20(1):41–9.

    Article  Google Scholar 

  6. Rothenberg KG. Assessment and Management of Psychiatric Symptoms in Neurodegenerative Disorders (Chapter 23) In: Neuro-Geriatrics (Ed.) Tousi Babak and Cummings Jeffrey 2017, Springer International Publishing AG. * (Comprehensive review of treatment of NPS in NDD).

  7. APA Practice Guideline Writing Group’s “Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia. https://doi.org/10.1176/appi.books.9780890426807.

  8. •• Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533–40 This Paper summarizes pharmacological properties of pimavanserin and results which led to its approval by FDA.

    Article  CAS  Google Scholar 

  9. Brodaty H, Arasaratnam C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry. 2012;169(9):946–53.

    Article  Google Scholar 

  10. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer’s disease. Parts I-IV. Br J Psychiatry. 1990;157:72–94.

    Article  CAS  Google Scholar 

  11. Rothenberg KG, Wiechers IR. Antipsychotics for neuropsychiatric symptoms of dementia—safety and efficacy in the context of informed consent. Psychiatr Ann. 2015;45(7):348–53.

    Article  Google Scholar 

  12. Lopez OL, Becker JT, Chang YF, Sweet RA, Aizenstein H, Snitz B, et al. The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer’s disease. Am J Psychiatry. 2013;170(9):1051–8.

    Article  Google Scholar 

  13. Paulsen JS, Salmon DP, Thal LJ, Romero R, Weisstein-Jenkins C, Galasko D, et al. Incidence of and risk factors for psychosis of Alzheimer’s disease. Neurology. 2000;54(10):1965–71.

    Article  CAS  Google Scholar 

  14. Wilkosz PA, Seltman HJ, Devlin B, Weamer EA, Lopez OL, DeKosky ST, et al. Trajectories of cognitive decline in Alzheimer’s disease. Int Psychogeriatr. 2010;22(2):281–90.

    Article  Google Scholar 

  15. Jeste D, Finkel S. Psychosis of Alzheimer’s disease and related dementias: diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatr. 2000;8(1):29–34.

    Article  CAS  Google Scholar 

  16. D'Onofrio G, Panza F, Sancarlo D, Paris FF, Cascavilla L, Mangiacotti A, et al. Delusions in patients with Alzheimer’s disease: a multidimensional approach. J Alzheimers Dis. 2016;51(2):427–37.

    Article  Google Scholar 

  17. Kuhl DE, Minoshima S, Fessler JA, Ficaro EP, Wieland DM, Koeppe RA, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer’s disease, and Parkinson’s disease. Ann Neurol. 1996;40(3):399–410.

    Article  CAS  Google Scholar 

  18. Koppel J, Acker C, Davies P, Lopez OL, Jimenez H, Azose M, et al. Psychotic Alzheimer’s disease is associated with gender-specific tau phosphorylation abnormalities. Neurobiol Aging. 2014 Sep;35(9):2021–8.

    Article  CAS  Google Scholar 

  19. Jacobson SA, Morshed T, Dugger BN, Beach TG, Hentz JG, Adler CH, et al. Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations. Parkinsonism Relat Disord. 2014 Sep;20(9):1009–14.

    Article  Google Scholar 

  20. Cummings JL, McRae T, Zhang R, The Donepezil-Sertraline Study Group. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry. 2006;14:605–11.

    Article  Google Scholar 

  21. Cummings J, Lai TJ, Hemrungrojn S, Mohandas E, Yun Kim S, Nair G, et al. Role of donepezil in the management of neuropsychiatric symptoms in Alzheimer’s disease and dementia with Lewy bodies. CNS Neurosci Ther. 2016 Mar;22(3):159–66.

    Article  CAS  Google Scholar 

  22. Herrmann N, Lanctôt KL, Hogan DB. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimers Res Ther. 2013;5(Suppl1):1–12.

    Google Scholar 

  23. Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology. 2004;63:214–9.

    Article  CAS  Google Scholar 

  24. Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease: a pooled analysis of 3 studies. J Clin Psychiatry. 2008;69(3):341–8.

    Article  CAS  Google Scholar 

  25. Devanand DP, Mintzer J, Schultz SK. Relapse risk after discontinuation of risperidone in Alzheimer’s disease. N Engl J Med. 2012;367:1497–507.

    Article  CAS  Google Scholar 

  26. Moretti R, Torre P, Antonello RM, Cazzato G, Griggio S, Bava A. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer’s disease and other dementias: a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen. 2003;18:205–14.

    Article  Google Scholar 

  27. Mintzer JE, Tune LE, Breder CD, Swanink R, Marcus RN, McQuade RD, et al. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry. 2007 Nov;15(11):918–31.

    Article  Google Scholar 

  28. Katz I, de Deyn PP, Mintzer J, Greenspan A, Zhu Y, Brodaty H. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer’s disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry. 2007 May;22(5):475–84.

    Article  Google Scholar 

  29. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2000;57(10):968–76.

    Article  CAS  Google Scholar 

  30. El-Saifi N, Moyle W, Jones C, Tuffaha H. Quetiapine safety in older adults: a systematic literature review. J Clin Pharm Ther. 2016 Feb;41(1):7–18.

    Article  CAS  Google Scholar 

  31. Ozawa C, Roberts R, Yoshida K, Suzuki T, Lebowitz B, Reeves S, et al. Placebo effects in the treatment of noncognitive symptoms of Alzheimer’s disease: analysis of the CATIE-AD data. J Clin Psychiatry. 2017;78(9):1204–10.

    Article  Google Scholar 

  32. Marsh L, Williams JR, Rocco M, Grill S, Munro C, Dawson TM. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology. 2004;293-300(32):63.

    Google Scholar 

  33. Fenelon G, Alves G. Epidemiology of psychosis in Parkinson’s disease. J Neurol Sci. 2010;289:12–7.

    Article  Google Scholar 

  34. Fenelon G, Soulas T, Zenasni F, de Langavant LC. The changing face of Parkinson’s disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord. 2010;25:755–9.

    Article  Google Scholar 

  35. Ravina B, Marder K, Fernandez HH, Friedman JH, McDonald W, Murphy D, et al. Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group. Mov Disord. 2007;22:1061–8.

    Article  Google Scholar 

  36. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain. 2000;123(Pt 4):733–45.

    Article  Google Scholar 

  37. Goetz CG, Fan W, Leurgans S. Antipsychotic medication treatment for mild hallucinations in Parkinson’s disease: positive impact on long-term worsening. Mov Disord. 2008;23(11):1541–5.

    Article  Google Scholar 

  38. Murai T, Muller U, Werheid K, et al. In vivo evidence for differential association of striatal dopamine and midbrainserotonin systems with neuropsychiatric symptoms in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2001;13:222–8.

    Article  CAS  Google Scholar 

  39. Huot P, Johnston TH, Darr T, Hazrati LN, Visanji NP, Pires D, et al. Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov Disord. 2010;25:1399–408.

    Article  Google Scholar 

  40. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 2002;125(pt 2):391–403.

    Article  CAS  Google Scholar 

  41. Goldman JG, Holden S. Treatment of psychosis and dementia in Parkinson’s disease. Curr Treat Options Neurol. 2014;16(3):281–99.

    Article  Google Scholar 

  42. Moretti R, Torre P, Antonello RM, Cazzato G, Griggio S, Bava A. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer’s disease and other dementias: a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen. 2003;18:205–14.

    Article  Google Scholar 

  43. Workman RH Jr, Orengo CA, Bakey AA, et al. The use of risperidonefor psychosis and agitation in demented patients with Parkinson disease. J Neuropsychiatry Clin Neurosci. 1997;9:594–7.

    Article  CAS  Google Scholar 

  44. Pollak P, Tison F, Rascol O, Destée A, Péré JJ, Senard JM, et al. Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75(5):689–95.

    Article  CAS  Google Scholar 

  45. Morgante L, Epifanio A, Spina E, Zappia M, Di Rosa AE, Marconi R, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol. 2004;27(4):153–6.

    Article  CAS  Google Scholar 

  46. Desmarais P, Massoud F, Filion J, Nguyen QD, Bajsarowicz P. Quetiapine for psychosis in Parkinson disease and neurodegenerative parkinsonian disorders: a systematic review. J Geriatr Psychiatry Neurol. 2016;29(4):227–36 Systematic review of effectiveness of quetiapine in PD psychosis.

    Article  Google Scholar 

  47. Hausner L, Damian M, Sartorius A, Frolich L. Efficacy and cognitive side effects of ECT in depressed elderly inpatients with co-existing mild cognitive impairment or dementia. J Clin Psychiatry. 2011;72:91–7.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cleveland Clinic Lou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH, 44195, USA

    Kasia Gustaw Rothenberg MD, PhD

  2. Department of Psychiatry, Yale School of Medicine, 300 George St., Suite 901, New Haven, CT, 06511, USA

    Ryan Rajaram MD, MSc

Authors
  1. Kasia Gustaw Rothenberg MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryan Rajaram MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kasia Gustaw Rothenberg MD, PhD.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Dementia

Electronic supplementary material

ESM 1

(DOCX 24 kb)

s

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rothenberg, K.G., Rajaram, R. Advances in Management of Psychosis in Neurodegenerative Diseases. Curr Treat Options Neurol 21, 3 (2019). https://doi.org/10.1007/s11940-019-0545-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11940-019-0545-6

Keywords

Search

Navigation